Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
3.7
4.7
Journals
Biomedicines
Special Issues
Role of Glycomics in Diagnosis and Prognosis of Cancers
share announcement

Role of Glycomics in Diagnosis and Prognosis of Cancers

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Molecular and Translational Medicine".

Deadline for manuscript submissions: 30 September 2024 | Viewed by 786

Special Issue Editor

Dr. Tijl Vermassen

E-Mail Website
Guest Editor
1. Department Medical Oncology, University Hospital Ghent, 9000 Ghent, Belgium
2. Department Basic and Applied Medicine, Ghent University, 9000 Ghent, Belgium
Interests: glycomics; protein chemistry; tumor immunology; biomarker research

Special Issue Information

Dear Colleagues,

A multitude of -omic fields are being studied for their involvement in cancer. In the last decade, there has been a lot of interest in the study of glycomics, the systematic study of all glycan structures, and its involvement in cancer. Glycans, formed as either free glycans or as a part of a more complex biomolecule (e.g., glycoproteins), participate in the majority of biological processes. For a long time, glycoproteins have been of great interest in biomarker research as many changes in protein chemistry can be associated with actual changes in protein glycosylation.

This variation seen in the glycome is the result of genetic and environmental factors, which also play a major role in the onset of many disease. Therefore, variations in glycosylation patterns have been linked to a multitude of pathological conditions, providing precious insight into the cellular functions underlying these pathological conditions. In this matter, aberrant glycosylation has been identified as a hallmark feature seen in the development and progression of cancer. Glycomics are, therefore, intensely studied as potential diagnostic and prognostic biomarker in various cancer types.

In this Special Issue, we aim to cover the most recent advances regarding glycomic research in cancer. The main focus will be on, but not limited to, the pathophysiological role of the glycome in cancer development and progression, use of glycans for disease diagnosis, risk stratification and prognosis through glycan variation, as well as innovative tools and methodological approaches to assess glycan-related biomarkers.

In this Special Issue, we welcome any kind of papers (reviews, original papers, perspective papers) on the aforementioned subject.

Dr. Tijl Vermassen
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • glycomics
  • cancer development
  • diagnosis
  • prognosis
  • risk stratification

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

15 pages, 1230 KiB  
Article
The Association between Urine N-Glycome and Prognosis after Initial Therapy for Primary Prostate Cancer
by Tijl Vermassen, Nicolaas Lumen, Charles Van Praet, Nico Callewaert, Joris Delanghe and Sylvie Rottey
Biomedicines 2024, 12(5), 1039; https://doi.org/10.3390/biomedicines12051039 - 8 May 2024
Viewed by 312
Abstract
Next to prostate-specific antigen, no biochemical biomarkers have been implemented to guide patient follow-up after primary therapy for localized prostate cancer (PCa). We evaluated the prognostic potential of urine N-glycome in terms of event-free survival (EFS) in patients undergoing primary therapy for [...] Read more.
Next to prostate-specific antigen, no biochemical biomarkers have been implemented to guide patient follow-up after primary therapy for localized prostate cancer (PCa). We evaluated the prognostic potential of urine N-glycome in terms of event-free survival (EFS) in patients undergoing primary therapy for PCa. The prognostic features of the urine N-glycosylation profile at diagnosis, assessed in 77 PCa patients, were determined in terms of EFS next to standard clinical parameters. The majority of patients were diagnosed with International Society of Urological Pathology grade ≤ 3 (82%) T1–2 tumors (79%) and without pelvic lymph node invasion (96%). The patients underwent active surveillance (14%), robot-assisted laparoscopic prostatectomy (48%), or external beam radiotherapy (37%). Decreased ratios of biantennary core-fucosylation were noted in patients who developed an event, which was linked to a shorter EFS in both the intention-to-treat cohort and all subcohort analyses. Combining the urine N-glycan biomarker with the D’Amico Risk Classification for PCa resulted in an improved nomogram for patient classification after primary therapy. The rate of urine N-glycan biantennary core-fucosylation, typically linked to more aggressive disease status, is lower in patients who eventually developed an event following primary therapy and subsequently in patients with a worse EFS. The combination of urine N-glycan biomarkers together with clinical parameters could, therefore, improve the post-therapy follow-up of patients with PCa. Full article
(This article belongs to the Special Issue Role of Glycomics in Diagnosis and Prognosis of Cancers)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop